PubMed:17255138 / 1068-1377 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"3905","span":{"begin":19,"end":26},"obj":"ChemicalEntity"},{"id":"3906","span":{"begin":104,"end":107},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3907","span":{"begin":118,"end":131},"obj":"ChemicalEntity"},{"id":"3908","span":{"begin":141,"end":148},"obj":"ChemicalEntity"},{"id":"3909","span":{"begin":162,"end":171},"obj":"ChemicalEntity"},{"id":"3910","span":{"begin":191,"end":200},"obj":"ChemicalEntity"},{"id":"3911","span":{"begin":220,"end":228},"obj":"ChemicalEntity"},{"id":"3912","span":{"begin":248,"end":258},"obj":"ChemicalEntity"},{"id":"3913","span":{"begin":281,"end":290},"obj":"ChemicalEntity"}],"attributes":[{"id":"A25","pred":"db_id","subj":"3905","obj":"MESH:D001241"},{"id":"A26","pred":"db_id","subj":"3906","obj":"MESH:D009203"},{"id":"A27","pred":"db_id","subj":"3907","obj":"MESH:D000082"},{"id":"A28","pred":"db_id","subj":"3908","obj":"MESH:D001241"},{"id":"A29","pred":"db_id","subj":"3909","obj":"MESH:C116926"},{"id":"A30","pred":"db_id","subj":"3910","obj":"MESH:C105934"},{"id":"A31","pred":"db_id","subj":"3911","obj":"MESH:D009288"},{"id":"A32","pred":"db_id","subj":"3912","obj":"MESH:D004008"},{"id":"A33","pred":"db_id","subj":"3913","obj":"MESH:D007052"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-sentences","denotations":[{"id":"T14","span":{"begin":0,"end":309},"obj":"Sentence"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T17","span":{"begin":104,"end":107},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":108,"end":110},"obj":"GeneOrGeneProduct"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T9","span":{"begin":104,"end":107},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A9","pred":"mondo_id","subj":"T9","obj":"0004781"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T6","span":{"begin":104,"end":107},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T5","span":{"begin":104,"end":107},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T27","span":{"begin":19,"end":26},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":104,"end":107},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":118,"end":131},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":141,"end":148},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":162,"end":171},"obj":"ChemicalEntity"},{"id":"T33","span":{"begin":191,"end":200},"obj":"ChemicalEntity"},{"id":"T35","span":{"begin":220,"end":228},"obj":"ChemicalEntity"},{"id":"T38","span":{"begin":248,"end":258},"obj":"ChemicalEntity"},{"id":"T40","span":{"begin":281,"end":290},"obj":"ChemicalEntity"}],"attributes":[{"id":"A27","pred":"ID:","subj":"T27","obj":"D001241"},{"id":"A28","pred":"ID:","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A29","pred":"ID:","subj":"T29","obj":"D000082"},{"id":"A30","pred":"ID:","subj":"T30","obj":"D001241"},{"id":"A31","pred":"ID:","subj":"T31","obj":"C116926"},{"id":"A32","pred":"ID:","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A33","pred":"ID:","subj":"T33","obj":"D000068579"},{"id":"A34","pred":"ID:","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A35","pred":"ID:","subj":"T35","obj":"D009288"},{"id":"A36","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A37","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A38","pred":"ID:","subj":"T38","obj":"D004008"},{"id":"A39","pred":"ID:","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_47381"},{"id":"A40","pred":"ID:","subj":"T40","obj":"D007052"},{"id":"A41","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A42","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T5","span":{"begin":104,"end":107},"obj":"OrganismTaxon"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T40","span":{"begin":281,"end":290},"obj":"ChemicalEntity"},{"id":"T38","span":{"begin":248,"end":258},"obj":"ChemicalEntity"},{"id":"T35","span":{"begin":220,"end":228},"obj":"ChemicalEntity"},{"id":"T33","span":{"begin":191,"end":200},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":162,"end":171},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":141,"end":148},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":118,"end":131},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":104,"end":107},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":19,"end":26},"obj":"ChemicalEntity"},{"id":"T47343","span":{"begin":104,"end":107},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T71975","span":{"begin":104,"end":107},"obj":"OrganismTaxon"}],"attributes":[{"id":"A42","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A41","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A40","pred":"ID:","subj":"T40","obj":"D007052"},{"id":"A39","pred":"ID:","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_47381"},{"id":"A38","pred":"ID:","subj":"T38","obj":"D004008"},{"id":"A37","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A36","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A35","pred":"ID:","subj":"T35","obj":"D009288"},{"id":"A34","pred":"ID:","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A33","pred":"ID:","subj":"T33","obj":"D000068579"},{"id":"A32","pred":"ID:","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A31","pred":"ID:","subj":"T31","obj":"C116926"},{"id":"A30","pred":"ID:","subj":"T30","obj":"D001241"},{"id":"A29","pred":"ID:","subj":"T29","obj":"D000082"},{"id":"A28","pred":"ID:","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A27","pred":"ID:","subj":"T27","obj":"D001241"},{"id":"A40604","pred":"#label","subj":"T47343","obj":"DISEASE"}],"text":"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."}